| 19.75 -0.52 (-2.57%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 25.57 | 1-year : | 29.87 |
| Resists | First : | 21.89 | Second : | 25.57 |
| Pivot price | 18.59 |
|||
| Supports | First : | 18.59 | Second : | 16.54 |
| MAs | MA(5) : | 18.82 |
MA(20) : | 19.02  |
| MA(100) : | 17.74 |
MA(250) : | 11.01 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 69.4 |
D(3) : | 50.2 |
| RSI | RSI(14): 52.6 |
|||
| 52-week | High : | 28.14 | Low : | 3.59 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ LBPH ] has closed below upper band by 18.9%. Bollinger Bands are 52.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 20.68 - 20.79 | 20.79 - 20.89 |
| Low: | 19.37 - 19.49 | 19.49 - 19.59 |
| Close: | 19.55 - 19.76 | 19.76 - 19.93 |
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which focuses on developing therapies for multiple neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.
Sat, 13 Apr 2024
Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) Short Interest Up 32.4% in March - MarketBeat
Tue, 02 Apr 2024
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
Wed, 27 Mar 2024
Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) is a favorite amongst institutional investors who own 50% - Yahoo Finance
Mon, 08 Jan 2024
Behind The Huge Rally In Longboard Pharmaceuticals (NASDAQ:LBPH) - Seeking Alpha
Sat, 06 Jan 2024
Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) Shares Could Be 28% Below Their Intrinsic Value Estimate - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 34 (M) |
| Shares Float | 24 (M) |
| Held by Insiders | 1.1 (%) |
| Held by Institutions | 64 (%) |
| Shares Short | 4,950 (K) |
| Shares Short P.Month | 3,190 (K) |
| EPS | -2.4 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.66 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -58.5 % |
| Return on Equity (ttm) | -106.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.69 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -51 (M) |
| Levered Free Cash Flow | -31 (M) |
| PE Ratio | -8.27 |
| PEG Ratio | 0 |
| Price to Book value | 11.82 |
| Price to Sales | 0 |
| Price to Cash Flow | -13.05 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|